Skip to Main Content

Cytokinetics and Amgen on Friday presented a deeper analysis from a large clinical trial of their chronic heart failure drug, showing a greater benefit for subgroups of patients with more advanced heart failure.

The new findings are somewhat better than the initial study results presented in October. However, the drug, omecamtiv mecarbil, still does not help heart failure patients live longer, so questions about its future — and Amgen’s commitment to it — remain unanswered.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!